State of the Science Summit Recaps

home / publications / supplements / state-of-the-science-summit-recaps
Lubna Naaz Chaudhary, MD, MS, associate professor, medicine, Medical College of Wisconsin

Ongoing and Planned Research Build on Prior Advancements in ER+/HER2– Breast Cancer

Ryan Scott
November 19th 2024
Article

Lubna Naaz Chaudhary, MD, MS, highlights the PARSIFAL and Young-PEARL trials and discusses ongoing research in ER-positive/HER2-negative breast cancer.

Breast Cancer

Data Continue to Help Shape CDK4/6 Inhibitor Selection, Sequencing in HR+ Breast Cancer

Ryan Scott
November 18th 2024
Article

Lubna Naaz Chaudhary, MD, MS, discusses selecting a CDK4/6 inhibitor in hormone receptor–positive breast cancer.

Tanios S. Bekaii-Saab, MD

Molecular Testing Helps First-Line Treatment Landscape Evolve in Pancreatic Cancer

Jax DiEugenio
November 17th 2024
Article

Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.

Kathleen N. Moore, MD, MS

Refined Definition of Platinum Resistance, Novel ADCs Could Bring More Changes to Ovarian Cancer Treatment

Jax DiEugenio
November 12th 2024
Article

Kathleen N. Moore, MD, MS, discusses the evolving treatment landscape of platinum-resistant ovarian cancer.

Kari Wisinski, MD, the Endowed Professor of Hematology and Oncology and chief of the Division of Hematology, Medical Oncology and Palliative Care in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health in Madison

Genomic Predictors Inform the Evolving Role of Chemotherapy in Breast Cancer Management

Ashling Wahner
November 12th 2024
Article

Kari Wisinski, MD, highlights treatments for HER2– breast cancer, the role of chemotherapy in TNBC, and the benefits of T-DXd for brain metastases.

Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center

AE Profiles and Dosing Schedules Define the Role of CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

Ashling Wahner
November 7th 2024
Article

Kari Wisinski, MD, discusses factors that influence her decision between CDK4/6 inhibitors for patients with treatment-naive, HR+ metastatic breast cancer.